Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 6, Pages 857–862
http://dx.doi.org/10.1155/2013/472845
Research Article

Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent Placement

1Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou 510080, China
2Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China

Received 14 August 2013; Revised 29 October 2013; Accepted 3 November 2013

Academic Editor: Olav Lapaire

Copyright © 2013 Anping Cai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. Reiner, A. L. Catapano, G. De Backer et al., “ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS),” European Heart Journal, vol. 32, no. 14, pp. 1769–1818, 2011. View at Google Scholar
  2. C. M. Gibson, Y. B. Pride, C. P. Hochberg, S. Sloan, M. S. Sabatine, and C. P. Cannon, “Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy,” Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2290–2295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Armitage, L. Bowman, K. Wallendszus et al., “Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial,” The Lancet, vol. 376, no. 9753, pp. 1658–1669, 2010. View at Google Scholar
  4. C. Baigent, L. Blackwell, J. Emberson et al., “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials,” The Lancet, vol. 376, no. 9753, pp. 1670–1681, 2010. View at Google Scholar
  5. T. Ohira, P. J. Schreiner, J. D. Morrisett, L. E. Chambless, W. D. Rosamond, and A. R. Folsom, “Lipoprotein(a) and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study,” Stroke, vol. 37, no. 6, pp. 1407–1412, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. C. P. Cannon, E. Braunwald, C. H. McCabe et al., “Intensive versus moderate lipid lowering with statins after acute coronary syndromes,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1495–1504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. J. C. LaRosa, S. M. Grundy, D. D. Waters et al., “Intensive lipid lowering with atorvastatin in patients with stable coronary disease,” The New England Journal of Medicine, vol. 352, no. 14, pp. 1425–1435, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. T. R. Pedersen, O. Faergeman, J. J. P. Kastelein et al., “High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: a randomized controlled trial,” Journal of the American Medical Association, vol. 294, no. 19, pp. 2437–2445, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. B. G. Nordestgaard, M. J. Chapman, K. Ray et al., “Lipoprotein(a) as a cardiovascular risk factor: current status,” European Heart Journal, vol. 31, no. 23, pp. 2844–2853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Tsimikas and J. L. Hall, “Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies,” Journal of the American College of Cardiology, vol. 60, no. 8, pp. 716–721, 2012. View at Google Scholar
  11. R. Clarke, J. F. Peden, J. C. Hopewell et al., “Genetic variants associated with Lp(a) lipoprotein level and coronary disease,” The New England Journal of Medicine, vol. 361, no. 26, pp. 2518–2528, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Cai, W. Li, Y. Zhang, Y. Mo, W. Mai, and Y. Zhou, “Lipoprotein(a): a promising marker for residual cardiovascular risk assessment,” Disease Markers, vol. 35, no. 5, pp. 551–559, 2013. View at Google Scholar
  13. L. Berglund and R. Ramakrishnan, “Lipoprotein(a): an elusive cardiovascular risk factor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 12, pp. 2219–2226, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. P. R. Kamstrup, “Lipoprotein(a) and ischemic heart disease-A causal association? A review,” Atherosclerosis, vol. 211, no. 1, pp. 15–23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. P. R. Kamstrup, M. Benn, A. Tybjærg-Hansen, and B. G. Nordestgaard, “Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study,” Circulation, vol. 117, no. 2, pp. 176–184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Luc, J.-M. Bard, D. Arveiler et al., “Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study,” Atherosclerosis, vol. 163, no. 2, pp. 377–384, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. J. S. Danik, N. Rifai, J. E. Buring, and P. M. Ridker, “Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women,” Journal of the American Medical Association, vol. 296, no. 11, pp. 1363–1370, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Cantin, F. Gagnon, S. Moorjani et al., “Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec cardiovascular study,” Journal of the American College of Cardiology, vol. 31, no. 3, pp. 519–525, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Danesh, R. Collins, and R. Peto, “Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies,” Circulation, vol. 102, no. 10, pp. 1082–1085, 2000. View at Google Scholar · View at Scopus
  20. Y. Momiyama, R. Ohmori, Z. A. Fayad et al., “Associations between serum lipoprotein(a) levels and the severity of coronary and aortic atherosclerosis,” Atherosclerosis, vol. 222, no. 1, pp. 241–244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. J. Nicholls, W. H. W. Tang, H. Scoffone et al., “Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy,” Journal of Lipid Research, vol. 51, no. 10, pp. 3055–3061, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. S. Virani, A. Brautbar, B. C. Davis et al., “Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: The Atherosclerosis Risk in Communities (ARIC) study,” Circulation, vol. 125, no. 2, pp. 241–249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Tsimikas and J. L. Witztum, “The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity,” Current Opinion in Lipidology, vol. 19, no. 4, pp. 369–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Hoover-Plow and M. Huang, “Lipoprotein(a) metabolism: potential sites for therapeutic targets,” Metabolism, vol. 62, no. 4, pp. 479–491, 2013. View at Google Scholar
  25. D. J. Grainger, P. R. Kemp, A. C. Liu, R. M. Lawn, and J. C. Metcalfe, “Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice,” Nature, vol. 370, no. 6489, pp. 460–462, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Kronenberg, M. F. Kronenberg, S. Kiechl et al., “Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the bruneck study,” Circulation, vol. 100, no. 11, pp. 1154–1160, 1999. View at Google Scholar · View at Scopus
  27. J. D. Spence and M. Koschinsky, “Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 7, pp. 1550–1551, 2012. View at Google Scholar